According to UroGen Pharma's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 17.7. At the end of 2024 the company had a P/S ratio of 6.08.
Year | P/S ratio | Change |
---|---|---|
2024 | 6.08 | 8.61% |
2023 | 5.60 | 75.89% |
2022 | 3.18 | -28.43% |
2021 | 4.45 | -86.87% |
2020 | 33.9 | -99.91% |
2019 | > 1000 | 6197.46% |
2018 | 619 | 929.77% |
2017 | 60.1 |